TScan Therapeutics Director Departs, Becomes Senior Advisor
Ticker: TCRX · Form: 8-K · Filed: 2026-04-02T07:30:07-04:00
Sentiment: neutral
Topics: management-change, consulting-agreement
Related Tickers: TCRX
TL;DR
TScan director Altschuler out, but in as CEO advisor. Consulting deal signed.
AI Summary
TScan Therapeutics, Inc. announced on March 31, 2026, the departure of Dr. Steven D. Altschuler from its Board of Directors. The company also appointed Dr. Altschuler as a Senior Advisor to the CEO, effective April 1, 2026, and entered into a consulting agreement with him.
Why It Matters
The departure of a director and subsequent appointment as a senior advisor can signal strategic shifts or a desire for specialized expertise in a company's leadership.
Risk Assessment
Risk Level: low — This filing primarily concerns a change in board composition and a consulting agreement, which typically carries low immediate risk.
Key Players & Entities
- TScan Therapeutics, Inc. (company) — The company filing the report.
- Dr. Steven D. Altschuler (person) — Departing director and newly appointed Senior Advisor.
- March 31, 2026 (date) — Effective date of departure.
- April 1, 2026 (date) — Effective date of Senior Advisor role.
FAQ
What was the effective date of Dr. Altschuler's departure from the Board of Directors?
Dr. Steven D. Altschuler's departure from the Board of Directors was effective March 31, 2026.
What new role has Dr. Altschuler taken on at TScan Therapeutics?
Dr. Altschuler has been appointed as a Senior Advisor to the CEO.
When did Dr. Altschuler's role as Senior Advisor become effective?
His role as Senior Advisor to the CEO became effective on April 1, 2026.
Has TScan Therapeutics entered into any agreements with Dr. Altschuler?
Yes, TScan Therapeutics has entered into a consulting agreement with Dr. Altschuler.
What is the CIK number for TScan Therapeutics, Inc.?
The CIK number for TScan Therapeutics, Inc. is 0001783328.
From the Filing
EDGAR Filing Documents for 0001193125-26-138973 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-138973 Filing Date 2026-04-02 Accepted 2026-04-02 07:30:07 Documents 11 Period of Report 2026-03-31 Items Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Interactive Data Document Format Files Seq Description Document Type Size 1 8-K d923169d8k.htm iXBRL 8-K 24142 Complete submission text file 0001193125-26-138973.txt 137843 Data Files Seq Description Document Type Size 2 XBRL TAXONOMY EXTENSION SCHEMA tcrx-20260331.xsd EX-101.SCH 2841 3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrx-20260331_lab.xml EX-101.LAB 17975 4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrx-20260331_pre.xml EX-101.PRE 11251 14 EXTRACTED XBRL INSTANCE DOCUMENT d923169d8k_htm.xml XML 3635 Mailing Address 830 WINTER STREET WALTHAM MA 02451 Business Address 830 WINTER STREET WALTHAM MA 02451 857-399-9500 TScan Therapeutics, Inc. (Filer) CIK : 0001783328 (see all company filings) EIN. : 825282075 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-40603 | Film No.: 26830624 SIC : 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)